17965-82-1

Basic information

• Product Name: 1,7-NAPHTHYRIDIN-8-AMINE
• Synonyms: 8-AMINO-1,7-NAPHTHYRIDINE;1,7-NAPHTHYRIDIN-8-AMINE;[1,7]Naphthyridin-8-ylaMine;1,7-Naphthyridin-8-amine, 8-Amino-1,7-diazanaphthalene;8-amino-1,7-naphthypridine
• CAS NO: 17965-82-1
• Molecular Formula: C₈H₇N₃
• Molecular Weight: 145.16
• Mol File: 17965-82-1.mol
• Article Data: 7

Chemical Properties

• Melting Point: 167-170°C
• Boiling Point: 343.301 °C at 760 mmHg
• Flash Point: 188.206 °C
• Appearance: /
• Density: 1.293 g/cm³
• Vapor Pressure: 0.00907mmHg at 25°C
• Refractive Index: 1.435
• Storage Temp.: 2-8°C(protect from light)
• PKA: 5.54±0.30(Predicted)
• CAS DataBase Reference: 1,7-NAPHTHYRIDIN-8-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,7-NAPHTHYRIDIN-8-AMINE(17965-82-1)
• EPA Substance Registry System: 1,7-NAPHTHYRIDIN-8-AMINE(17965-82-1)

Safety Data

• Hazard Codes: Xi,T
• Statements: 36/37/38-36-25
• Safety Statements: 26-36/37/39-45
• Hazardous Substances Data: 17965-82-1(Hazardous Substances Data)

Usage

Uses

1,7-Naphthyridin-8-amine is a useful chemical in organic synthesis.

InChI:InChI=1/C6H4F3NO3/c1-2-10-3(5(11)12)4(13-2)6(7,8)9/h1H3,(H,11,12)

Upstream product

• 253-69-0 [1,7]naphthyridine 
• 452-58-4 2,3-Diaminopyridine 
• 56-81-5 glycerol 

Downstream Products

• 909649-06-5 5-bromo-8-chloro-[1,7]naphthyridine 
• 67967-17-3 8-amino-5-bromo-1,7-naphthyridine 
• 13058-77-0 8-chloro-[1,7]naphthyridine 
• 651310-81-5 7-benzenesulfonyl-6-methylsulfanyl-4,5,8atriaza-phenanthren-8-ylideneamine monotrifluoroacetate 
• 1351516-28-3 8-imino-1,7-naphthyridin-7(8H)-amine 2,4,6-trimethylbenzenesulfonate 
• 1201802-79-0 C₁₇H₁₃N₃O₂S 
• 67967-11-7 8-hydroxy-1,7-naphthyridine 
• 958254-67-6 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine 

Relevant articles and documents

ALPHA, BETA-UNSATURATED AMIDE COMPOUND

An object of the present invention is to provide an α,β-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like. The α,β-unsaturated amide compound represented by the following formula (I) or a pharmaceutically acceptable salt or the like thereof has anticancer activity and the like: [wherein, "A" represents optionally substituted heterocyclic diyl, R1 represents hydrogen atom or optionally substituted lower alkyl, R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents -O-, -S-, -SO2-, -NRX1- (wherein, RX1 represents hydrogen atom or lower alkyl), -CHRX2- (wherein, RX2 represents hydrogen atom or hydroxy), -CH=CH-, -CO- or -NH-CO-, and n1 and n2 are the same or different, and each represents 0 or 1].

a, ? UNSATURATED AMIDE COMPOUND

The present invention provides an α,β-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like represented by the following formula (I): [wherein, "A" represents optionally substituted heterocyclic diyl, R1 represents hydrogen atom or optionally substituted lower alkyl, R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents -O-, -S-, -SO2-, -NRX1- (wherein, RX1 represents hydrogen atom or lower alkyl), -CHRX2- (wherein, RX2 represents hydrogen atom or hydroxy), -CH=CH-, -CO- or -NH-CO-, and n1 and n2 are the same or different, and each represents 0 or 1].

HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.